NCT04535063 is a Phase 3 clinical trial of COVID19 convalescent plasma infusion in Covid19 Pneumonia, sponsored by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno.

Who is sponsoring NCT04535063?

NCT04535063 is sponsored by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno.

What drugs are being tested in NCT04535063?

Interventions in NCT04535063: COVID19 convalescent plasma infusion.

What condition does NCT04535063 study?

NCT04535063 studies Covid19 Pneumonia.

Is NCT04535063 still recruiting?

NCT04535063 is currently completed. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT04535063

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia

Completed Phase 3 Last updated 19 July 2022

What this trial tests

Phase 3 trial testing COVID19 convalescent plasma infusion in Covid19 Pneumonia in 200 participants. Completed in 25 February 2021.

Timeline

18 April 2020

Primary endpoint
30 December 2020

25 February 2021

Quick facts

Lead sponsor	Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	18 April 2020
Primary completion	30 December 2020
Estimated completion	25 February 2021
Sites	1 location across Argentina

Drugs / interventions tested

COVID19 convalescent plasma infusion — full drug profile →

Conditions studied

Covid19 Pneumonia — all drugs for Covid19 Pneumonia →

Sponsor

Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno — full company profile →

Who can join

18 and older, any sex, with Covid19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Chavda VP, Bezbaruah R, Dolia S, Shah N, et al · · 2023 · cited 10× · PMID 36741339 · DOI 10.1016/j.procbio.2023.01.018

Verify or expand the search:

Other Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno trials

Trials by the same sponsor.

NCT05752201 — ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine · Phase 2, PHASE3 · completed
NCT05576402 — Endoscopic Scoring System Utilization in Inflammatory Bowel Disease · unknown
NCT04395105 — Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial · Phase 3 · terminated
NCT04627337 — Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04535063 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04535063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing